KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary
Mayo Clinic · Mayo Clinic in Arizona · +38 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
79
total citations
- FWCI
- 108.60
- Percentile
- 100%
- References
- 32
Citations per year
Authors
30- VEVicente E. TorresCorresponding
Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic in Florida
- CACurie Ahn
Seoul National University, Seoul National University Hospital
- TRThijs R.M. Barten
Radboud University Nijmegen, Radboud University Medical Center
- GBGodela Brosnahan
University of Colorado Anschutz Medical Campus, University of Colorado Denver
- MAMelissa A. Cadnapaphornchai
Children's Hospital of Philadelphia
Topics & keywords
Topics
Keywords
- Guideline
- Autosomal dominant polycystic kidney disease
- Medicine
- Executive summary
- Kidney disease
- Disease
- Intensive care medicine
- Polycystic kidney disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- ASAmerican Society of Hematology
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- WHWorld Health Organization
- GSGilead Sciences
- APAlexion Pharmaceuticals
- CCCleveland Clinic
- DDanone
- ISInternational Society of Nephrology
- VPVertex Pharmaceuticals
- AAcceleron
- MTMaze Therapeutics
- BHBayer HealthCare
- NNierstichting
- OPOtsuka Pharmaceutical
- SServier
- OPOno Pharmaceutical
- IIpsen
- NINational Institutes of Health
- MRMedical Research Council
- NHNational Health and Medical Research Council
- NINational Institute of Diabetes and Digestive and Kidney Diseases
- JPJanssen Pharmaceuticals